Pfeifer Christian G, Fisher Matthew B, Carey James L, Mauck Robert L
McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Translational Musculoskeletal Research Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA 19104, USA. Department of Trauma Surgery, Regensburg University Medical Center, 93053 Regensburg, Germany.
McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Translational Musculoskeletal Research Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA 19104, USA. Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, and North Carolina State University, Raleigh, NC 27695, USA.
Sci Transl Med. 2015 Oct 21;7(310):310re9. doi: 10.1126/scitranslmed.aac7019.
Promising therapies for cartilage repair are translated through large animal models toward human application. To guide this work, regulatory agencies publish recommendations ("guidance documents") to direct pivotal large animal studies. These are meant to aid in study design, outline metrics for judging efficacy, and facilitate comparisons between studies. To determine the penetrance of these documents in the field, we synthesized the recommendations of the American Society for Testing and Materials, U.S. Food and Drug Administration, and European Medicines Agency into a scoring system and performed a systematic review of the past 20 years of preclinical cartilage repair studies. Our hypothesis was that the guidance documents would have a significant impact on how large animal cartilage repair studies were performed. A total of 114 publications meeting our inclusion criteria were reviewed for adherence to 24 categories extracted from the guidance documents, including 11 related to study design and description and 13 related to study outcomes. Overall, a weak positive trend was observed over time (P = 0.004, R(2) = 0.07, slope = 0.63%/year), with overall adherence (the sum of study descriptors and outcomes) ranging from 32 ± 16% to 58 ± 14% in any individual year. There was no impact of the publication of the guidance documents on adherence (P = 0.264 to 0.50). Given that improved adherence would expedite translation, we discuss the reasons for poor adherence and outline approaches to increase and promote their more widespread adoption.
用于软骨修复的有前景的疗法正通过大型动物模型转化为人类应用。为指导这项工作,监管机构发布建议(“指导文件”)以指导关键的大型动物研究。这些文件旨在协助研究设计、概述判断疗效的指标,并促进研究之间的比较。为确定这些文件在该领域的渗透率,我们将美国材料与试验协会、美国食品药品监督管理局和欧洲药品管理局的建议整合为一个评分系统,并对过去20年的临床前软骨修复研究进行了系统综述。我们的假设是,指导文件将对大型动物软骨修复研究的开展方式产生重大影响。我们审查了总共114篇符合纳入标准的出版物,以确定其是否符合从指导文件中提取的24个类别,其中包括11个与研究设计和描述相关的类别以及13个与研究结果相关的类别。总体而言,随着时间的推移观察到了微弱的积极趋势(P = 0.004,R(2) = 0.07,斜率 = 0.63%/年),在任何一年中,总体依从性(研究描述符和结果的总和)范围为32 ± 16%至58 ± 14%。指导文件的发布对依从性没有影响(P = 0.264至0.50)。鉴于提高依从性将加快转化进程,我们讨论了依从性差的原因,并概述了提高和促进其更广泛采用的方法。